AUM Biosciences Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AUM Biosciences Pte. Ltd. - overview
Established
2018
Location
Singapore, -, Singapore
Primary Industry
Biotechnology
About
AUM Biosciences Pte. Ltd. is a biotechnology company focused on the development of precision oncology therapeutics to effectively combat cancer resistance through innovative drug solutions. AUM Biosciences Pte.
Ltd. was founded in 2018, headquartered in Singapore. The company specializes in the development of precision oncology solutions. Vishal Doshi serves as both founder and CEO.
AUM Biosciences has secured two major deals, with the most recent funding round being a Series A on April 3, 2023, in which the company raised USD 17. 45 mn led by Everlife Holdings Pte Ltd, with participation from Agency for Science, Technology and Research and Sprim Ventures. The total amount raised to date stands at USD 17. 45 mn, leading to a current company valuation of USD 97.
71 mn. AUM Biosciences specializes in precision oncology therapeutics addressing cancer resistance challenges. Their investigational therapies include AUM001, AUM601, AUM302, and AUM003, targeting specific pathways vital for tumor survival and proliferation. The company caters to healthcare institutions, oncologists, and research organizations across the United States, Australia, and China, focusing on patients with resistant cancer types.
In 2023, AUM Biosciences reported zero revenue and an EBITDA of USD -10,389,437. 40. The company's revenue model is primarily based on partnerships with healthcare institutions, involving B2B transactions and potential revenue from milestone payments, licensing agreements, and product sales following regulatory approvals. AUM001 and AUM601 are highlighted as flagship products in clinical development.
Following the successful Series A funding of USD 17. 45 mn in April 2023, AUM Biosciences plans to utilize these funds to accelerate pipeline expansion and business growth. The company aims to advance the clinical development of two Phase II programs for MNK and TRK inhibitors. AUM Biosciences is also exploring opportunities to expand into new markets, with specific geographic regions targeted for growth in the coming years.
Current Investors
Pureland Global Venture, Anexa Capital, ASA Capital Partners, LLC
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.aumbiosciences.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.